Paper39476283
Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.
Ogieuhi IJ and 11 others. High Blood Press Cardiovasc Prev, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials. Papers, record 39476283. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39476283
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dyslipidemias | Major topic |
| Oligonucleotides, Antisense | Major topic |
| Lipids | Major topic |
| Hypolipidemic Agents | Major topic |
| Humans | |
| Treatment Outcome | |
| Biomarkers | |
| Apolipoprotein B-100 | |
| Clinical Trials as Topic |
Source PubMed
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29361723 | Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. | Pharmacy (Basel) | 2018 | https://conductscience.org/library/papers/29361723 | PubMed |
| 2 | 36614969 | Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia. | J Clin Med | 2022 | https://conductscience.org/library/papers/36614969 | PubMed |
| 3 | 30500603 | Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. | Atherosclerosis | 2019 | https://conductscience.org/library/papers/30500603 | PubMed |
| 4 | 20378080 | Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. | J Am Coll Cardiol | 2010 | https://conductscience.org/library/papers/20378080 | PubMed |
| 5 | 22247890 | The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. | J Adv Pharm Technol Res | 2011 | https://conductscience.org/library/papers/22247890 | PubMed |
| 6 | 35902351 | Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. | J Clin Lipidol | 2022 | https://conductscience.org/library/papers/35902351 | PubMed |
| 7 | 31103643 | Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. | Am J Med | 2019 | https://conductscience.org/library/papers/31103643 | PubMed |
| 8 | 23542898 | Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. | Circ Res | 2013 | https://conductscience.org/library/papers/23542898 | PubMed |
| 9 | 32178672 | Dyslipidemia and cardiovascular disease risk among the MASHAD study population. | Lipids Health Dis | 2020 | https://conductscience.org/library/papers/32178672 | PubMed |
| 10 | 22388933 | Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. | Hum Mol Genet | 2012 | https://conductscience.org/library/papers/22388933 | PubMed |
| 11 | 32646313 | Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. | Expert Opin Pharmacother | 2020 | https://conductscience.org/library/papers/32646313 | PubMed |
| 12 | 31390500 | Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31390500 | PubMed |
| 13 | 25614280 | Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. | Arterioscler Thromb Vasc Biol | 2015 | https://conductscience.org/library/papers/25614280 | PubMed |
| 14 | 33123354 | Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. | Clin Kidney J | 2020 | https://conductscience.org/library/papers/33123354 | PubMed |
| 15 | 12489851 | Antisense oligonucleotides: basic concepts and mechanisms. | Mol Cancer Ther | 2002 | https://conductscience.org/library/papers/12489851 | PubMed |
| 16 | 21418033 | Antisense oligonucleotides for the treatment of dyslipidemia. | Curr Pharm Des | 2011 | https://conductscience.org/library/papers/21418033 | PubMed |
| 17 | 23060426 | Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. | Circulation | 2012 | https://conductscience.org/library/papers/23060426 | PubMed |
| 18 | 24992960 | Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. | Nucleic Acids Res | 2014 | https://conductscience.org/library/papers/24992960 | PubMed |
| 19 | 32604776 | Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. | J Clin Med | 2020 | https://conductscience.org/library/papers/32604776 | PubMed |
| 20 | 75545 | Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. | Proc Natl Acad Sci U S A | 1978 | https://conductscience.org/library/papers/75545 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42582720 | Gene Therapy for Lipid Management: Dawn of a New Era. | Cureus | 2026 | https://conductscience.org/library/papers/42582720 | PubMed |
| 41514470 | TMEM105 upregulation promotes colorectal cancer malignancy: a novel prognostic biomarker potentially linked to the MYC-Ribosome biogenesis axis. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/41514470 | PubMed |
| 41023586 | Genomic medicine in hepatology: mechanisms and liver treatment strategies. | Mol Med | 2025 | https://conductscience.org/library/papers/41023586 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APOB | 338 | PubTator's text mining | https://conductscience.org/library/genes/338 | NCBI Gene |
| APOC3 | 345 | PubTator's text mining | https://conductscience.org/library/genes/345 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39476283
GET https://conductscience.org/api/papers/v1/39476283/references?page=2